New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
10:42 EDTMNKD, PLUG, KING, VHC, NWBO, ACHN, ARWR, JCP, YPF, AMPEOptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR VHC AMPE ACHN KING YPF NWBO PLUG JCP MNKD
News For ARWR;VHC;AMPE;ACHN;KING;YPF;NWBO;PLUG;JCP;MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 24, 2015
10:26 EDTJCPStocks with call strike movement; TWTR JCP
Twitter (TWTR) December 40 call option implied volatility increased 1% to 44, J.C. Penney (JCP) November 20 call option implied volatility decreased 5% to 42 according to IVolatility.
June 23, 2015
07:36 EDTACHNJMP Securities to hold a conference
Subscribe for More Information
June 22, 2015
08:31 EDTAMPEAmpio announces additional study ersults for Optina
Ampio announced that further data analysis from the 12-week multi-center, placebo-controlled, double-masked randomized trial identified a reversal of pathological changes and a synergistic effect with other medication. As previously reported, oral treatment with Optina has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal thickness in patients with diabetic macular edema when given the optimal dose. An independent specialized ophthalmology company reviewed a representative set of images of the eye from the trial and identified positive changes in Optina treated patients compared to placebo. These changes included the reversal of complications such as cystic lesions and subretinal fluid. Additionally, analysis revealed that 69% of the patients in the Optina™ Study received a standard of care medication that manages kidney-induced high blood pressure. The drugs referred to as ACE Inhibitors or ARBs are commonly prescribed to diabetic patients. When this group received the optimal Optina™ dose, they showed a six-letter improvement compared to placebo, regardless of whether or not they previously had anti-VEGF eye injections. There was a significant 34 micron reduction in central retinal thickness over placebo. 60% of these eyes showed a restoration of at least one line of vision compared to only 27% of placebo.
June 17, 2015
07:36 EDTARWRArrowhead receives regulatory clearance for additional Phase 2b ARC-520 studies
Arrowhead Research announced that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis B infection, has been approved by Germany’s Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are expected shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies. The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1. For each patient, the duration of the study is approximately 33 weeks, from screening to the Day 169 follow-up visit. For each study, a planning interim analysis will be performed when 54 patients have completed their Day 71 visit. This analysis will be used to plan future studies only and will not impact the enrollment or conduct of Heparc-2002 and -2003. Based on the interim results, the company will decide whether higher multiple-doses would be likely to lead to increased activity, in which case higher doses may be evaluated in one or more additional studies. The primary objective of the 2002 and 2003 studies is to evaluate the depth of hepatitis B surface antigen decline in response to multiple doses of ARC-520 compared to placebo as a measure of drug activity. Secondary objectives include the assessment of safety and tolerability and multi-dose pharmacokinetics of ARC-520 when co-administered with entecavir or tenofovir, in addition to other exploratory objectives.
June 15, 2015
16:00 EDTMNKDOptions Update; June 15, 2015
Subscribe for More Information
09:19 EDTACHNBiotech Industry Organization to hold a conference
BIO 2015 is being held in Philadelphia on June 15-18.
08:03 EDTJCPMasterCard adding tokenization support for private label credit cards
Subscribe for More Information
05:53 EDTMNKDStocks with implied volatility movement; MNKD NFLX
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use